Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HOLLY L HAKE HARRIS

Allopathic & Osteopathic Physicians Dermatology

NPI
1538159207
CMS profile
890706
Location
SOUTH BEND, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$448.39

16 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $448.39 16

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Organogenesis Inc. $148.05 2
ABBVIE INC. $102.88 5
E.R. Squibb & Sons, L.L.C. $102.38 5
Lilly USA, LLC $42.25 2
Amgen Inc. $29.86 1
Fresenius Kabi USA, LLC $22.97 1

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HOLLY L HAKE HARRIS

NPI 1538159207 · CMS profile ID 890706

Allopathic & Osteopathic Physicians / Dermatology

SOUTH BEND, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538159207?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HOLLY L HAKE HARRIS, NPI 1538159207, CMS profile ID 890706. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538159207?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). HOLLY L HAKE HARRIS, NPI 1538159207, CMS profile ID 890706. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538159207?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
HOLLY L HAKE HARRIS, NPI 1538159207, CMS profile ID 890706, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1538159207?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

16 matching records · $448.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 16 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–16 of 16.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $15.7112/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015498277 CMS
Organogenesis Inc. $23.0511/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048149045 CMS
Fresenius Kabi USA, LLC $22.9711/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060095123 CMS
E.R. Squibb & Sons, L.L.C. $21.4509/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015498237 CMS
ABBVIE INC. $28.8007/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997418761 CMS
ABBVIE INC. $26.4407/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997418759 CMS
E.R. Squibb & Sons, L.L.C. $21.7407/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015498201 CMS
Lilly USA, LLC $20.9205/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031478009 CMS
Organogenesis Inc. $125.0004/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048149049 CMS
Amgen Inc. $29.8604/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020588395 CMS
Lilly USA, LLC $21.3303/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031576159 CMS
E.R. Squibb & Sons, L.L.C. $21.7403/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015498105 CMS
ABBVIE INC. $16.0103/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997418757 CMS
ABBVIE INC. $15.8802/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997418755 CMS
E.R. Squibb & Sons, L.L.C. $21.7401/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015498085 CMS
ABBVIE INC. $15.7501/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997418753 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,931.99 7
PY2021 $29.68 2
PY2022 $77.19 4
PY2023 $448.39 16
PY2024 $189.69 8
PY2025 $60.71 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,042.82 1
PY2025 Principal investigator $214,389.75 98
PY2024 Recipient $6,347.66 1
PY2024 Principal investigator $293,318.73 162
PY2023 Principal investigator $348,782.35 197
PY2022 Recipient $100.00 2
PY2022 Principal investigator $164,469.18 81
PY2021 Principal investigator $449,676.56 73
PY2020 Recipient $15,456.30 2
PY2020 Principal investigator $642,662.67 80
PY2019 Recipient $418,491.34 8
PY2019 Principal investigator $1,194,399.32 72

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

83 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $7,837.20 12/16/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905247985
Principal investigator 1 ABBVIE INC. $279.30 12/08/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889823821
Principal investigator 1 Incyte Corporation $102.75 12/02/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248029
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $232.70 11/23/2022 Non-covered Recipient Entity
Stamford Therapeutics
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 933188545
Principal investigator 1 Incyte Corporation $8,799.30 11/18/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905247983
Principal investigator 1 ABBVIE INC. $268.50 11/16/2022 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 889820977
Principal investigator 1 ABBVIE INC. $279.30 11/09/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889819621
Principal investigator 1 PFIZER INC. $1,722.50 11/05/2022 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949734661
Principal investigator 1 Incyte Corporation $32.50 11/01/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248005
Principal investigator 1 Incyte Corporation $40.84 11/01/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248007
Principal investigator 1 Incyte Corporation $12.51 11/01/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248009
Principal investigator 1 Incyte Corporation $75.54 11/01/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248011
Principal investigator 1 Incyte Corporation $50.04 11/01/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248013
Principal investigator 1 Incyte Corporation $0.77 11/01/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248015
Principal investigator 1 Incyte Corporation $65.00 11/01/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248017
Principal investigator 1 Incyte Corporation $61.26 11/01/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248019
Principal investigator 1 Incyte Corporation $100.72 11/01/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248021
Principal investigator 1 Incyte Corporation $0.88 11/01/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248023
Principal investigator 1 Incyte Corporation $25.02 11/01/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248025
Principal investigator 1 Incyte Corporation $0.66 11/01/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248027
Principal investigator 1 Incyte Corporation $32.50 11/01/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248033
Principal investigator 1 Incyte Corporation $50.04 11/01/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248035
Principal investigator 1 Incyte Corporation $50.04 11/01/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248037
Principal investigator 1 Incyte Corporation $65.00 11/01/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248039
Principal investigator 1 Incyte Corporation $50.04 11/01/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248041
Principal investigator 1 Incyte Corporation $65.00 11/01/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248043
Principal investigator 1 Incyte Corporation $61.26 11/01/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248045
Principal investigator 1 Incyte Corporation $32.50 11/01/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248047
Principal investigator 1 Incyte Corporation $50.04 11/01/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248049
Principal investigator 1 Incyte Corporation $75.54 11/01/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248051
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,503.10 10/27/2022 Non-covered Recipient Entity
Burke Pharmaceutical Research
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 933188389
Principal investigator 1 Incyte Corporation $13,127.40 10/21/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905247981
Principal investigator 1 ABBVIE INC. $558.60 10/12/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889814677
Principal investigator 1 PFIZER INC. $1,722.50 10/08/2022 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949738959
Principal investigator 1 Incyte Corporation $25.02 10/04/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905247987
Principal investigator 1 Incyte Corporation $10.21 10/04/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905247989
Principal investigator 1 Incyte Corporation $30.63 10/04/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905247991
Principal investigator 1 Incyte Corporation $48.78 10/04/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905247993
Principal investigator 1 Incyte Corporation $2.16 10/04/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905247995
Principal investigator 1 Incyte Corporation $3.55 10/04/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905247997
Principal investigator 1 Incyte Corporation $113.31 10/04/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905247999
Principal investigator 1 Incyte Corporation $48.75 10/04/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248001
Principal investigator 1 Incyte Corporation $0.77 10/04/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248003
Principal investigator 1 Incyte Corporation $48.75 10/04/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905248031
Principal investigator 1 PFIZER INC. $1,595.10 09/23/2022 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949743639
Recipient Eli Lilly and Company $15.00 09/09/2022 Covered Recipient Physician A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 917810785
Principal investigator 1 ABBVIE INC. $1,117.20 09/07/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889808559
Principal investigator 1 ABBVIE INC. $81.00 09/05/2022 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 889808267
Principal investigator 1 ABBVIE INC. $1,388.00 08/24/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889807505
Principal investigator 1 PFIZER INC. $1,544.40 08/24/2022 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949736171
Principal investigator 1 ABBVIE INC. $417.30 08/22/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889807305
Principal investigator 1 Incyte Corporation $3,250.80 08/19/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905247979
Principal investigator 1 ABBVIE INC. $2,773.70 08/10/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889804411
Principal investigator 1 PFIZER INC. $3,445.00 08/10/2022 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949738941
Principal investigator 1 ABBVIE INC. $2,153.00 07/15/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889801295
Principal investigator 1 Incyte Corporation $1,789.20 07/15/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905247977
Principal investigator 1 ABBVIE INC. $1,935.80 07/14/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889800873
Recipient Eli Lilly and Company $85.00 07/11/2022 Covered Recipient Physician A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 917811577
Principal investigator 1 ABBVIE INC. $1,970.30 07/05/2022 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 889798385
Principal investigator 1 PFIZER INC. $1,722.50 06/25/2022 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949734837
Principal investigator 1 Incyte Corporation $1,233.00 06/17/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905247975
Principal investigator 1 Incyte Corporation $1,625.40 05/20/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905247973
Principal investigator 1 ABBVIE INC. $4,969.50 05/11/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889790869
Principal investigator 1 PFIZER INC. $1,722.50 04/22/2022 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949733439
Principal investigator 1 Incyte Corporation $1,734.30 04/18/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905247971
Principal investigator 1 ABBVIE INC. $1,656.50 04/14/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889785699
Principal investigator 1 ABBVIE INC. $13,049.20 04/12/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889785245
Principal investigator 1 PFIZER INC. $1,544.40 03/24/2022 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949743483
Principal investigator 1 Incyte Corporation $7,153.20 03/21/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905247969
Principal investigator 1 ABBVIE INC. $1,970.30 03/09/2022 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 889780089
Principal investigator 1 Eli Lilly and Company $234.00 03/08/2022 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 917840929
Principal investigator 1 Eli Lilly and Company $12,352.00 03/07/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 917828525
Principal investigator 1 Eli Lilly and Company $1,200.00 03/07/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 917836535
Principal investigator 1 PFIZER INC. $3,266.90 03/03/2022 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949732167
Principal investigator 1 ABBVIE INC. $1,491.40 02/22/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889778189
Principal investigator 1 Incyte Corporation $3,000.00 02/18/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905247961
Principal investigator 1 Incyte Corporation $1,100.00 02/18/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905247963
Principal investigator 1 Incyte Corporation $11,500.00 02/18/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905247965
Principal investigator 1 Incyte Corporation $2,500.00 02/18/2022 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905247967
Principal investigator 1 Eli Lilly and Company $5,142.00 02/08/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 917837439
Principal investigator 1 Eli Lilly and Company $527.00 02/08/2022 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 917842143
Principal investigator 1 PFIZER INC. $1,722.50 02/05/2022 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949732085
Principal investigator 1 Eli Lilly and Company $20,829.00 01/18/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 No dispute reported 06/30/2026 917828519

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $0.00 1
PY2025 Value of interest $109,356.47 1
PY2024 Amount invested $2,443.72 1
PY2024 Value of interest $109,356.47 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $106,912.75 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $154,320.92 1
PY2021 Amount invested $0.00 1
PY2021 Value of interest $88,340.48 1
PY2020 Amount invested $0.00 1
PY2020 Value of interest $80,642.76 1
PY2019 Amount invested $80,595.00 1
PY2019 Value of interest $806,985.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

7 records · PY2019–2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 Digital Diagnostics Inc. $0.00 $109,356.47 Shares Owned by Immediate Family (Ben Clark) Immediate family member No dispute reported 06/30/2026 1254605365
PY2024 Digital Diagnostics Inc. $2,443.72 $109,356.47 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 1153967797
PY2023 Digital Diagnostics Inc. $0.00 $106,912.75 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 1060331987
PY2022 Digital Diagnostics Inc. $0.00 $154,320.92 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 961154523
PY2021 Digital Diagnostics Inc. $0.00 $88,340.48 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 855625849
PY2020 Digital Diagnostics Inc. $0.00 $80,642.76 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 737170185
PY2019 IDx Technologies Inc. $80,595.00 $806,985.00 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 676471935